Infants with cystic fibrosis have altered fecal functional capacities with potential clinical and metabolic consequences.

BMC Microbiology
Alexander EngElhanan Borenstein

Abstract

Infants with cystic fibrosis (CF) suffer from gastrointestinal (GI) complications, including pancreatic insufficiency and intestinal inflammation, which have been associated with impaired nutrition and growth. Recent evidence identified altered fecal microbiota taxonomic compositions in infants with CF relative to healthy infants that were characterized by differences in the abundances of taxa associated with GI health and nutrition. Furthermore, these taxonomic differences were more pronounced in low length infants with CF, suggesting a potential link to linear growth failure. We hypothesized that these differences would entail shifts in the microbiome's functional capacities that could contribute to inflammation and nutritional failure in infants with CF. To test this hypothesis, we compared fecal microbial metagenomic content between healthy infants and infants with CF, supplemented with an analysis of fecal metabolomes in infants with CF. We identified notable differences in CF fecal microbial functional capacities, including metabolic and environmental response functions, compared to healthy infants that intensified during the first year of life. A machine learning-based longitudinal metagenomic age analysis of healthy and...Continue Reading

References

Feb 1, 1986·Antimicrobial Agents and Chemotherapy·H SakataH Yoshioka
Mar 1, 1988·Pediatric Research·G N Thompson, G P Davidson
Aug 1, 1993·Gut·S O'BrienJ E Hegarty
Jun 1, 1997·Journal of the American College of Nutrition·J D SkinnerM McLeod
Feb 14, 2003·Lancet·Francisco Guarner, Juan-R Malagelada
May 22, 2004·BioTechniques·Zhongtang Yu, Mark Morrison
Oct 27, 2004·Proceedings of the National Academy of Sciences of the United States of America·Fredrik BäckhedJeffrey I Gordon
Nov 13, 2009·Nutrition Reviews·Steven H Zeisel, Kerry-Ann da Costa
Feb 6, 2010·The Journal of Pediatrics·UNKNOWN Cystic Fibrosis FoundationFrank J Accurso
Jan 19, 2012·Nutrients·Marco A R VinoloRui Curi
Nov 16, 2012·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Gwen DuytschaeverPeter Vandamme
Apr 23, 2013·Cell Metabolism·Thomas Q de Aguiar VallimPeter A Edwards
Jun 22, 2013·Cold Spring Harbor Perspectives in Medicine·Robert C De Lisle, Drucy Borowitz
Sep 26, 2013·Current Opinion in Pulmonary Medicine·Drucy Borowitz, Daniel Gelfond
Oct 8, 2013·Nature Reviews. Immunology·Charlie G Buffie, Eric G Pamer
Nov 2, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lucas R HoffmanSamuel I Miller
Mar 15, 2014·Current Opinion in Gastroenterology·Jason M RidlonJasmohan S Bajaj
Mar 19, 2014·The American Journal of Pathology·Xingshen SunJohn F Engelhardt
Jun 5, 2014·Nature·Sathish SubramanianJeffrey I Gordon
Aug 16, 2014·Journal of Proteome Research·Jiangjiang ZhuDaniel Raftery
Nov 18, 2014·Nature Methods·Benjamin BuchfinkDaniel H Huson
Mar 21, 2015·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Judith GrotheWolfgang Bernhard
May 15, 2015·Cell Host & Microbe·Fredrik BäckhedWang Jun
Oct 18, 2015·Nucleic Acids Research·Minoru KanehisaMao Tanabe
Nov 18, 2015·Scientific Reports·Jocelyn M ChooGeraint B Rogers
Mar 22, 2016·Trends in Microbiology·Andrés Moya, Manuel Ferrer
Mar 24, 2016·Applied Microbiology and Biotechnology·Huibin ZouJunhong Liu
May 4, 2016·Lancet·J Stuart Elborn
Jun 21, 2016·Cell Metabolism·Annika WahlströmFredrik Bäckhed
Sep 7, 2016·Frontiers in Microbiology·Silvia ArboleyaR Paul Ross
Nov 9, 2016·Proceedings of the National Academy of Sciences of the United States of America·Jing YanJulia F Charles
Apr 1, 2017·BMC Microbiology·Christine M BassisUNKNOWN CDC Prevention Epicenters Program
Apr 16, 2017·Paediatric Respiratory Reviews·Roisin DunwoodyNicholas Simmonds
Apr 25, 2017·JAMA Pediatrics·Daniel H LeungUNKNOWN Baby Observational and Nutrition Study (BONUS) Investigators of the Cystic Fibrosis Foundation Therapeutics Development Netw
Oct 19, 2017·Frontiers in Medicine·Verónica Urdaneta, Josep Casadesús
Nov 2, 2017·Trends in Microbiology·Francesca TurroniMarco Ventura
Mar 4, 2018·Microbiome·Alexander Eng, Elhanan Borenstein
Sep 12, 2018·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Ivo P van de PeppelJohan W Jonker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacteriotherapy

Bacteriotherapy, also known as fecal transplantation, involves the transfer of stool from a healthy donor into the gastrointestinal tract for the purpose of treating recurrent C. difficile colitis. Here is the latest on bacteriotherapy.

Bacteriotherapy (ASM)

Bacteriotherapy, also known as fecal transplantation, involves the transfer of stool from a healthy donor into the gastrointestinal tract for the purpose of treating recurrent C. difficile colitis. Here is the latest on bacteriotherapy.